These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25976701)

  • 1. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
    Valensi P; de Pouvourville G; Benard N; Chanut-Vogel C; Kempf C; Eymard E; Moisan C; Dallongeville J
    Diabetes Metab; 2015 Jun; 41(3):231-8. PubMed ID: 25976701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes.
    Takatori S; Hamada Y; Tanaka A; Akiyama S; Namba H; Tanaka M; Kawasaki H; Araki H
    Clin Ther; 2016 Feb; 38(2):398-403. PubMed ID: 26804641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
    Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study.
    Goldshtein I; Karasik A; Melzer-Cohen C; Engel SS; Yu S; Sharon O; Brodovicz K; Gadir N; Katzeff HL; Radican L; Chodick G; Shalev V; Tunceli K
    J Diabetes Complications; 2016; 30(7):1354-9. PubMed ID: 27320183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].
    Simonyi G; Ferenci T
    Orv Hetil; 2016 Apr; 157(16):618-22. PubMed ID: 27063429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
    Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.